What is HC Wainwright's Estimate for DMAC Q3 Earnings?

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for DiaMedica Therapeutics to a loss of $0.20 per share from a prior estimate of $0.21, while maintaining a “Buy” rating and $12 price target.
• DiaMedica reported a Q2 loss of $0.19 per share, beating the consensus estimate of a $0.20 loss by $0.01. The firm’s full-year 2026 EPS estimate is a loss of $0.80.
• Analyst sentiment is broadly positive, with four Buy ratings and one Sell rating producing a “Moderate Buy” consensus; the stock recently traded at $6.84, versus a 52-week range of $4.90 to $10.42.

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Free Report) - Research analysts at HC Wainwright increased their Q3 2026 EPS estimates for shares of DiaMedica Therapeutics in a report issued on Tuesday, August 11th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($0.20) for the quarter, up from their prior estimate of ($0.21). HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for DiaMedica Therapeutics' current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics' Q4 2026 earnings at ($0.22) EPS, FY2026 earnings at ($0.80) EPS, FY2027 earnings at ($0.98) EPS, FY2028 earnings at ($0.60) EPS, FY2029 earnings at ($0.27) EPS and FY2030 earnings at ($0.01) EPS.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.01.

DMAC has been the subject of a number of other research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of DiaMedica Therapeutics in a research report on Friday, July 17th. Wall Street Zen upgraded shares of DiaMedica Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday, June 6th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $12.00.

DiaMedica Therapeutics Stock Performance

DiaMedica Therapeutics stock opened at $6.84 on Thursday. DiaMedica Therapeutics has a fifty-two week low of $4.90 and a fifty-two week high of $10.42. The company has a market capitalization of $368.54 million, a price-to-earnings ratio of -9.50 and a beta of 1.01. The stock has a fifty day moving average of $6.66 and a two-hundred day moving average of $6.93.

Institutional Investors Weigh In On DiaMedica Therapeutics

Several hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp acquired a new stake in shares of DiaMedica Therapeutics in the second quarter worth approximately $829,000. Bank of America Corp DE increased its position in DiaMedica Therapeutics by 62.5% during the first quarter. Bank of America Corp DE now owns 42,768 shares of the company's stock worth $290,000 after purchasing an additional 16,446 shares during the last quarter. Renaissance Technologies LLC purchased a new position in DiaMedica Therapeutics during the first quarter worth approximately $356,000. Sei Investments Co. raised its stake in DiaMedica Therapeutics by 100.0% during the first quarter. Sei Investments Co. now owns 111,320 shares of the company's stock worth $754,000 after purchasing an additional 55,660 shares during the period. Finally, World Investment Advisors boosted its holdings in shares of DiaMedica Therapeutics by 7.7% in the 4th quarter. World Investment Advisors now owns 36,975 shares of the company's stock valued at $294,000 after purchasing an additional 2,650 shares during the last quarter. 10.12% of the stock is owned by institutional investors and hedge funds.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc NASDAQ: DMAC is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company's lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica's research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source